The $1.5 billion project builds on more than $3 billion the global biopharmaceutical company has already invested in its United States operations since 2018 and is expected to create at least 300 new jobs alongside hundreds of construction roles.
CSL expands US manufacturing with $1.5bn investment to boost plasma therapy production
March 10, 2026 Latest NewsBioPharma
Latest Video
New Stories
-
US launches investigation into pharmaceutical pricing with potential broad implications
June 23, 2026 - - Latest News -
Access delays in cancer medicines are costing Australia productivity, livelihoods, and lives
June 23, 2026 - - Latest News -
If we're incapable of delivering meaningful change, we should hope the US intervenes
June 23, 2026 - - Latest News -
'AUScelerate' emerges as new name for MTPConnect ahead of BIO 2026
June 22, 2026 - - Australian Biotech -
CSL executive Elizabeth Rex joins AusBiotech board as observer
June 22, 2026 - - Latest News -
It seems that one critical stakeholder group is missing in this website design
June 22, 2026 - - Latest News -
May 2026 delivers paediatric dosing flexibility, vaccine decisions, and policy updates
June 22, 2026 - - Latest News


